Laura Esserman, MD

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, discusses screening patients with higher-risk DCIS.

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, comments on the findings from the I-SPY 1 trial and the basis for the I-SPY 2 trial in patients with breast cancer.